Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vipadenant - Celgene

Drug Profile

Vipadenant - Celgene

Alternative Names: BG-14; BIIB-014; BIIB14; CEB-4520; V2006; VER-11135; VER-A00-11; VER-A00049; VER-ADO-49; VR-2006

Latest Information Update: 23 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Biogen Idec; Juno Therapeutics
  • Class Antineoplastics; Antiparkinsonians; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2 receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Parkinson's disease

Most Recent Events

  • 23 May 2019 Vipadenant is still in preclinical trials for cancer (Combination therapy) in USA (Vernalis pipeline, May 2019)
  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top